Clinical Trial: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760155) titled 'A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus' on Aug. 07.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus (SLE)

Intervention: DRUG: ESG206

Anti-BAFF-R Monoclonal Antibody

DRUG: ESG206

Anti-BAFF-R Monoclonal Antibody

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sp...